000 01278 a2200349 4500
005 20250517184919.0
264 0 _c20190826
008 201908s 0 0 eng d
022 _a1468-3083
024 7 _a10.1111/jdv.14700
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aHuilaja, L
245 0 0 _aA slowly developed severe cutaneous adverse reaction to idelalisib.
_h[electronic resource]
260 _bJournal of the European Academy of Dermatology and Venereology : JEADV
_cMay 2018
300 _ae192-e193 p.
_bdigital
500 _aPublication Type: Case Reports; Letter
650 0 4 _aClass Ia Phosphatidylinositol 3-Kinase
_xmetabolism
650 0 4 _aDrug-Related Side Effects and Adverse Reactions
650 0 4 _aEnzyme Inhibitors
_xadverse effects
650 0 4 _aHumans
650 0 4 _aMale
650 0 4 _aMiddle Aged
650 0 4 _aPurines
_xadverse effects
650 0 4 _aQuinazolinones
_xadverse effects
650 0 4 _aSkin
_xdrug effects
700 1 _aLindgren, O
700 1 _aSoronen, M
700 1 _aSiitonen, T
700 1 _aTasanen, K
773 0 _tJournal of the European Academy of Dermatology and Venereology : JEADV
_gvol. 32
_gno. 5
_gp. e192-e193
856 4 0 _uhttps://doi.org/10.1111/jdv.14700
_zAvailable from publisher's website
999 _c27800967
_d27800967